Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.
Sikander Ailawadhi, MD, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses potential combination strategies with selinexor (Xpovio) and belantamab mafodotin-blmf (Blenrep) in multiple myeloma.
The approvals of selinexor and belantamab mafodotin have offered the potential to introduce novel combination strategies to the relapsed/refractory multiple myeloma paradigm. Moreover, combination regimens with these agents could include proteasome inhibitors, such as bortezomib (Velcade) or carfilzomib (Kyprolis), immunomodulatory agents, such as lenalidomide (Revlimid) or pomalidomide (Pomalyst), or monoclonal antibodies, such as daratumumab (Darzalex), explains Ailawadhi.
The question of which combinations will offer patients the most benefit remains unanswered, Ailawadhi says. In addition to clinical benefit, it’s important to look at the toxicity profile of the regimen to ensure that it does not compromise safety for patients, concludes Ailawadhi.